$5.14
0.224.47%
At close: -
$5.06
-0.08-1.56%
After Hours: 7:45 PM EDT
Comments
Loading...
Emergent BioSolutions Analyst Ratings and Price Targets | NYSE:EBS | Benzinga
Emergent BioSolutions Inc has a consensus price target of $25.86 based on the ratings of 8 analysts. The high is $55 issued by Chardan Capital on November 9, 2022. The low is $12 issued by Benchmark on November 7, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on April 1, 2025, March 21, 2025, and March 4, 2025, respectively. With an average price target of $15 between HC Wainwright & Co., there's an implied 196.44% upside for Emergent BioSolutions Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Benchmark
Rodman & Renshaw
Rodman & Renshaw
Chardan Capital
1calculated from analyst ratings
Analyst Ratings for Emergent BioSolutions
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/01/2025 | Buy Now | 196.44% | HC Wainwright & Co. | Raghuram Selvaraju43% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 03/21/2025 | Buy Now | 196.44% | HC Wainwright & Co. | Raghuram Selvaraju43% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 03/04/2025 | Buy Now | 196.44% | HC Wainwright & Co. | Raghuram Selvaraju43% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 01/21/2025 | Buy Now | 196.44% | HC Wainwright & Co. | Raghuram Selvaraju43% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 01/10/2025 | Buy Now | 196.44% | HC Wainwright & Co. | Raghuram Selvaraju43% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 12/30/2024 | Buy Now | 196.44% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $15 | Initiates | → Buy | Get Alert |
| 11/07/2024 | Buy Now | 137.15% | Benchmark | Robert Wasserman49% | $8 → $12 | Maintains | Buy | Get Alert |
| 09/13/2024 | Buy Now | 216.21% | Rodman & Renshaw | Brandon Folkes41% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 08/22/2024 | Buy Now | 216.21% | Rodman & Renshaw | — | → $16 | Initiates | → Buy | Get Alert |
| 08/16/2024 | Buy Now | 58.1% | Benchmark | Robert Wasserman49% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2024 | Buy Now | 58.1% | Benchmark | Robert Wasserman49% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 07/03/2024 | Buy Now | 58.1% | Benchmark | Robert Wasserman49% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 07/02/2024 | Buy Now | 58.1% | Benchmark | Robert Wasserman49% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 06/24/2024 | Buy Now | 58.1% | Benchmark | Robert Wasserman49% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 06/21/2024 | Buy Now | 58.1% | Benchmark | Robert Wasserman49% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2024 | Buy Now | 58.1% | Benchmark | Robert Wasserman49% | $5 → $8 | Maintains | Buy | Get Alert |
| 04/11/2024 | Buy Now | -1.19% | Benchmark | Robert Wasserman49% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2024 | Buy Now | -1.19% | Benchmark | Robert Wasserman49% | → $5 | Upgrade | Hold → Buy | Get Alert |
| 11/20/2023 | Buy Now | — | JP Morgan | Jessica Fye67% | — | Reinstates | → Underweight | Get Alert |
| 08/29/2023 | Buy Now | — | Benchmark | Robert Wasserman49% | — | Downgrade | Buy → Hold | Get Alert |
| 05/31/2023 | Buy Now | 334.78% | Benchmark | Robert Wasserman49% | → $22 | Reiterates | Buy → Buy | Get Alert |
| 05/19/2023 | Buy Now | 334.78% | Benchmark | Robert Wasserman49% | → $22 | Reiterates | Buy → Buy | Get Alert |
| 04/10/2023 | Buy Now | 334.78% | Benchmark | Robert Wasserman49% | → $22 | Upgrade | Hold → Buy | Get Alert |
| 03/17/2023 | Buy Now | 77.87% | JP Morgan | Jessica Fye67% | $23 → $9 | Downgrade | Neutral → Underweight | Get Alert |
| 11/10/2022 | Buy Now | — | Benchmark | Robert Wasserman49% | — | Downgrade | Buy → Hold | Get Alert |
| 11/09/2022 | Buy Now | 986.96% | Chardan Capital | Keay Nakae55% | $65 → $55 | Maintains | Buy | Get Alert |
| 09/12/2022 | Buy Now | 473.12% | Cowen & Co. | Boris Peaker50% | $30 → $29 | Maintains | Market Perform | Get Alert |
| 05/04/2022 | Buy Now | 650.99% | Wells Fargo | Jacob Hughes42% | $46 → $38 | Maintains | Equal-Weight | Get Alert |
FAQ
What is the target price for Emergent BioSolutions (EBS) stock?
The latest price target for Emergent BioSolutions (NYSE:EBS) was reported by HC Wainwright & Co. on April 1, 2025. The analyst firm set a price target for $15.00 expecting EBS to rise to within 12 months (a possible 196.44% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Emergent BioSolutions (EBS)?
The latest analyst rating for Emergent BioSolutions (NYSE:EBS) was provided by HC Wainwright & Co., and Emergent BioSolutions reiterated their buy rating.
When was the last upgrade for Emergent BioSolutions (EBS)?
The last upgrade for Emergent BioSolutions Inc happened on March 7, 2024 when Benchmark raised their price target to $5. Benchmark previously had a hold for Emergent BioSolutions Inc.
When was the last downgrade for Emergent BioSolutions (EBS)?
The last downgrade for Emergent BioSolutions Inc happened on August 29, 2023 when Benchmark changed their price target from N/A to N/A for Emergent BioSolutions Inc.
When is the next analyst rating going to be posted or updated for Emergent BioSolutions (EBS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Emergent BioSolutions, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Emergent BioSolutions was filed on April 1, 2025 so you should expect the next rating to be made available sometime around April 1, 2026.
Is the Analyst Rating Emergent BioSolutions (EBS) correct?
While ratings are subjective and will change, the latest Emergent BioSolutions (EBS) rating was a reiterated with a price target of $15.00 to $15.00. The current price Emergent BioSolutions (EBS) is trading at is $5.06, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
